asx pxs
- Home
- asx pxs
Public
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Latest Articles
First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
Parkinson’s UK, in collaboration with Australian researchers, has taken a major step towards preventing the development of Parkinson’s disease with the first Australian patient in a Phase 2 clinical trial having been dosed with PXS-4708, a novel drug aimed at tackling Parkinson’s before its onset, along with other neurodegenerative disorders. The multi-national trial was initiated
Read MorePublic
Pharmaxis accelerates clinical drug developments with additional resources via sale of mannitol business to Arna Pharma
With a burgeoning pipeline of drugs deeply advanced, clinical stage biopharmaceuticals company Pharmaxis (ASX: PXS) has streamlined its business with the sale of its mannitol respiratory business (MBU) and will now will focus their resources towards a much larger commercial opportunity in blood cancers haematological malignancies, aka blood cancers. The definitive sale agreement of its
Read MorePublic
Garvan Institute preclinical study identifies potential of Pharmaxis drug to boost pancreatic cancer survival rate by 35%
Each year, more than 4,000 Australians are diagnosed with pancreatic cancer, a form of cancer which is difficult to diagnose and with limited treatment options. Thanks to a new study conducted by the Garvan Institute of Medical Research, however, a drug developed by biotech company Pharmaxis (ASX: PXS) could increase patient survival rates by 35%.
Read MorePublic
Encouraged by interim data, FDA approves Pharmaxis to expand its myelofibrosis treatment trials
Fresh off reporting final interim data from their Phase 2 clinical trials for PXS-5505 to treat myelofibrosis, biotech company Pharmaxis (ASX: PXS) has quickly jumped forward in the commercialisation process having been cleared by the US Food and Drug Administration (FDA) to commence a combination arm of the trial. The clearance of the amended trial
Read MorePublic
Pharmaxis delivers impressive Phase 2 clinical data to treat myelofibrosis, pushing on to FDA discussions
In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the final interim data analysis of their Phase 2 clinical trials for PXS-5505, a promising drug aimed at combating the debilitating effects of myelofibrosis. The data revealed 60% of trial patients experienced a significant improvement in
Read MorePublic
Pharmaxis progresses FDA discussions, set to expand bone marrow cancer trial to treat more patients
A large cohort of patients around the world diagnosed with myelofibrosis (aka bone marrow cancer) will soon be able to access a new treatment which has already shown to be effective in a small group of patients undergoing treatment of PXS-5505 in Phase 2 clinical trials. Myelofibrosis is a rare cancer of the bone marrow
Read MorePublic
